Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
Collaboration to drive diagnostics exports, tap high-growth regional markets and build scalable commercialization platform
New appointments bring diagnostics and medtech expertise to strengthen healthcare delivery and policy engagement
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
The agreements aim to strengthen medicine quality, patient safety and pharmaceutical research in India
Multi-stakeholder initiative highlights inclusive sports pathways, honours neurodivergent athletes, and calls for systemic reforms
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
The transition from an outsourced MRI model to an in-house facility marks more than an infrastructure upgrade
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
Subscribe To Our Newsletter & Stay Updated
